Navigation Links
Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
Date:7/1/2011

NUEDEXTA® is the first and only FDA-approved treatment for pseudobulbar affect (PBA). NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias. The primary outcome measure, laughing and crying episodes, was significantly lower in the NUEDEXTA arm compared to placebo. The secondary outcome measure, the Center for Neurologic Studies Lability Scale (CNS-LS), demonstrated a significantly greater mean decrease in CNS-LS score from baseline for the NUEDEXTA arm compared to placebo.

NUEDEXTA Important Safety Information

NUEDEXTA can interact with other medications causing significant changes in blood levels of those medications and/or NUEDEXTA. NUEDEXTA is contraindicated in patients receiving drugs that both prolong QT interval and are metabolized by CYP2D6 (e.g., thioridazine and pimozide) and should not be used concomitantly with other drugs containing quinidine, quinine, or mefloquine. NUEDEXTA is contraindica
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
9. AVANIR Pharmaceuticals Appoints Gregory J. Flesher to Senior Vice President and Chief Business Officer
10. Avanir Pharmaceuticals to Present at Three Conferences in March
11. Avanir Pharmaceuticals to Present at BioCentury Future Leaders in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 McGraw-Hill Education Professional, a ... science, technical, and medical communities, has announced the launch ... mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all iOS ... able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... Mass. , July 29, 2014  Instrumentation Laboratory (IL) ... including a new corporate logo. This is part of a ... Founded in Boston, MA , ... family of companies since 1992.  Other companies in the group ... Biokit and Systelab ( Barcelona, Spain ).  Like ...
(Date:7/29/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes MobileHelp with the 2014 North ... Value Leadership. MobileHelp,s leadership in flexibility across in-home ... progression in personal emergency response, and exemplifies key ... MobileHelp is at the forefront of convenience ...
Breaking Medicine Technology:McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Instrumentation Laboratory Unveils New Corporate Brand 2Instrumentation Laboratory Unveils New Corporate Brand 3Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3
... 2007 - Elixir,Pharmaceuticals, Inc., announced today new ... method for regulating,metabolism, decreasing body weight and ... poster sessions during ENDO 07, The,Endocrine Society's ... Elixir is focused on the development of ...
... - Metabasis Therapeutics,Inc. (Nasdaq:MBRX), a biopharmaceutical company ... novel drugs for the,treatment of metabolic and ... the liver and liver pathways, announced,today that ... Society's,89th Annual Meeting in Toronto, Canada., Both ...
Cached Medicine Technology:Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 2Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 3Elixir Pharmaceuticals Presents Additional Preclinical Data,Demonstrating the Potential of Ghrelin Antagonism to Regulate,Metabolism, Body Weight and Glycemic Control 4Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 2Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 3Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting 4
(Date:7/29/2014)... 2014 Summer is here, and that means it’s ... hike, swimming in a pool or laying out on the beach. ... ticks. The Puppy Store is here to help pet owners protect ... It’s almost impossible to completely keep fleas and ticks at bay, ... chances of their pets coming into contact with fleas and ticks. ...
(Date:7/29/2014)... 2014 A team of scientists, led ... PhD, has developed a blood test for Alzheimer’s disease ... development of Alzheimer’s disease interventions, according to an article ... puzzle, and this study represents one of several pieces ... past couple of years,” Ethell said. , The study, ...
(Date:7/29/2014)... cure most cases of cancer is to surgically remove ... is that the surgeon may fail to extract the ... a new technique, researchers at the University of Pennsylvania ... the entire tumor in the patient, increasing the likelihood ... injectable dye that accumulates in cancerous tissues much more ...
(Date:7/29/2014)... 29, 2014 As testosterone treatment lawsuits ... Bernstein Liebhard LLP notes that a new study is ... Type 2 diabetes. The research, which was published online ... June 30th, involved 88 men who suffered from Type ... aging male symptoms and erectile dysfunction. Roughly half of ...
(Date:7/29/2014)... Gerontological Society of America (GSA) and the National ... MD, PhD, of Columbia University as the 2014 recipient ... and Aging. , This award recognizes and honors the ... the field of creativity and aging shifted the conceptual ... and potential. Cohen inspired individuals to approach longevity asking ...
Breaking Medicine News(10 mins):Health News:Protect Dogs From Fleas and Ticks During the Summer 2Health News:Professor Develops Blood Test for Alzheimer’s Disease Risk 2Health News:Penn team makes cancer glow to improve surgical outcomes 2Health News:Penn team makes cancer glow to improve surgical outcomes 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Charon to receive 2014 Gene D. Cohen Award 2
... to hold sway on the degree of hangover one might ... has found. //Scottish researchers delved into this arena, and studied ... the clever lot benefit by being hangover less as compared ... ,The discomfort associated with a hangover, characterized by an unbearable ...
... Lilly Jaffe a six-year-old girl diagnosed with type 1 Diabetes ... of Chicago Medical Center on August 14. // Four days ... way to manufacturing insulin in her own body and ready ... started school., ,As she continued to do well, ...
... that severely ill malaria patients would benefit a lot ... Researchers from the Imperial College in London and experts ... replace fluids for children ill with malaria. ... the children who received the new treatment died, researchers ...
... report by Commonwealth Fund, employers are deducting health benefits ... cope with rising health care costs. // The higher ... to take individual insurance find it too expensive. Low-income ... may not have needed health care. ,An ...
... have great potentials in the fields of medicine and ... Dots (QDs) prove to be useful in advanced therapies ... ,A complete review of the latest literature and ... the nanotechnology website AzoNano. ,The review by Sandeep ...
... heart failure and men with treated prostate cancer are among ... Now, under new guidelines co-authored by a Hopkins cardiologist and ... Transplantation (ISHLT), they can and should be considered. ,“People ... have a chance to get a new heart,” says Stuart ...
Cached Medicine News:Health News:Molecular Medicine And Diabetes 2Health News:Molecular Medicine And Diabetes 3Health News:Molecular Medicine And Diabetes 4Health News:Molecular Medicine And Diabetes 5Health News:Molecular Medicine And Diabetes 6Health News:Molecular Medicine And Diabetes 7Health News:Most people applying for coverage end up not buying it 2Health News:Most people applying for coverage end up not buying it 3Health News:Now, Even Older Adults and Some Cancer Patients can go for Heart Transplantation 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: